The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism
NCT ID: NCT00611416
Last Updated: 2009-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2005-11-30
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss
NCT00692731
Long-term Effects of Green Tea on Gut Flora, Fat Absorption, Body Composition and Resting Energy Expenditure
NCT01556321
Effects of a Thermogenic Dietary Supplement on Metabolic, Hemodynamic, and Mood Responses
NCT03678116
Evaluation of Metabolism-Boosting Beverages
NCT01029236
Dose Response Bioavailability of Coffee and Green Tea Antioxidants in Humans
NCT01089920
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Green tea is made from the leaves of Camellia sinensis species of the Theaceae family. Green tea is the non- fermented/oxidised products, in contrast to black tea that is fully fermented/oxidised. Green teas contain high quantities of catechins and caffeine which are believed to be the active components affecting energy metabolism. EGCG is the most abundant catechin and has received the most attention (Yang et al., 2000). Caffeine represents approximately 3 to 5 % of the dry weight of green tea (Dufresne et al., 2001, Yang et al., 2000). It is general accepted that caffeine consumption is related to an increase in EE (Astrup et al., 1990), whereas the relation between catechins and energy metabolism is recently discovered.
In a study by Dulloo et al (1999), ten healthy men were assigned to 3 treatments: 1) green tea extract containing 150 mg/day caffeine and 270 mg/day of EGCG, 2) caffeine (150 mg/day) or 3) placebo. Ingestion of green tea extract (taken with each meal) increased 24-h EE by 4 % (328 kJ), reflecting its stimulatory effect on thermogenesis. This study also found a reduction in the respiratory quotient (RQ) during the green tea extract treatment, suggesting an increase in fat oxidation. However, Kovacs et al. (2004) did not report any changes in 24-h EE or RQ after same supplementation with green tea capsules, which may be explained by different background caffeine consumption.
Recently, two medium term studies have reported of increased fat oxidation after 8 and 12 weeks, respectively, supplementation with tea catechin containing beverage (Ota et al., 2005, Harada et al., 2005). In addition, Nagao et al. (2005) have shown that a daily consumption of tea beverage containing 690 mg/day catechins for 12 weeks reduced body fat area by 8% compared to the control group. Thus, catechins may not only promote EE, but also mildly reduce body fat.
Several potential mechanisms responsible for the altered energy and fat metabolism have been proposed. Dulloo et al. (1999) have suggested a synergistic interaction between catechins and caffeine due to sympathetically released noradrenaline (NA). Since catechins are known to be capable of inhibiting catechol O-methyltransferase (COMT) (the enzyme that degrades NA) (Borchardt \& Huber, 1975), and caffeine to inhibit trancellular phosphodiesterases (enzymes that break down NA-induced cAMP), it is proposed that the green tea extract, via its catechins polyphenols and caffeine, is effective in stimulating thermogenesis by relieving inhibition at different control points along the NA-cAMP axis. Taken together, both caffeine and tea catechins would be expected to increase and/or prolong the stimulatory effects of norepinephrine on energy and lipid metabolism.
Several animal studies have been conducted to elucidate the anti-obese mechanisms of green tea extracts.
* Increased hepatic β-oxidation of fatty acids in mice after 4 weeks high fat diet with supplementation with tea catechins (74% EGCg, 18% ECg, 6% GCg, 2% others) (Murase et al., 2002 and 4 weeks high fat diet with supplementation with EGCg (Klaus et al., 2005). On the other hand, fatty acid synthase (FAS) was not altered by tea catechins, which may indicate that the simulation of fatty acid oxidation, rather than suppression of lipogenesis, is the predominant contribution (Murase et al., 2002).
* Modulated appetite and reduces food intake through the leptin receptor-independent pathway (Kao et al., 2000)
* Intraperitoneal administration of EGCg may reduce the diet digestibility resulting in increased faecal excretion of lipids (Klaus et al., 2005)
* Green tea extract (8% caffeine and 25% catechins (\~70% EGCg)) stimulates brown adipose tissue thermogenesis and energy expenditure, which may be due to the prolonged effect of noradrenalin (Dulloo et al., 2000).
Large variations in catechin content and chemical structures occur during preparation and manufacturing of green tea products and therefore also among the studies. EGCg is the most intensely studied catechin. However, the plasma bioavailability of EGCg is lower than of EGC and EG (Henning et al., 2004), suggesting that non-galloylated catechins are better absorbed than the galloylated (Manach et al., 2005).
In addition, it is not known whether epimerization of catechins alters the effect on energy and fat metabolism (Harada et al., 2005, Ota et al., 2005, Xu et al., 2004). Therefore, it is not clear whether the reported effects are due to the total quantity of catechins, the chemical structure of specific catechins (e.g. epimerization and galloylation), and/or the caffeine content or other components of in the mix.
Methods
The study is a 5-way crossover double blind placebo controlled design. At each test day, energy expenditure and fat oxidation are measured via indirect calorimetry for 13 hours in one of two whole body respiratory chambers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Active treatment A
green tea
different catechin combinations
Mix of catechins and caffeine
3 tablet a day
2
Active treatment B
green tea
different catechin combinations
EGCG
3 tablets a day
3
Active treatment C
green tea
different catechin combinations
EGC
3 tablets a day
4
Positive control
Caffeine
3 tablets a day
5
Placebo
Placebo
3 tablets a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
green tea
different catechin combinations
Mix of catechins and caffeine
3 tablet a day
EGCG
3 tablets a day
EGC
3 tablets a day
Caffeine
3 tablets a day
Placebo
3 tablets a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-40 years
* BMI 18,5-25 kg/m2
Exclusion Criteria
* Hypertensive medication
* Increased Blood Pressure \> 140/85
* Hyperlpidimia
* Chronic disease (i.e. HIV)
* Use of any diet supplements including vitamins (during and 3 months prior to the study).
* High alcohol intake (\>21 units a week)
* High caffeine intake (\>250 mg/day) or high catechin intake (\>200 mg/day)
* Smoking
* Elite sports performer
* Use of any regular medication
18 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Unilever R&D
INDUSTRY
University of Copenhagen
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arne Astrup, Proffessor
Role: STUDY_CHAIR
Insitute of Human Nutrition
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Human Nutrition, The Royal Veterinary and Agricultrual University
Frederiksberg C, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Unilever
Identifier Type: -
Identifier Source: secondary_id
(KF) 01 279421
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.